Quality by Design Approach for the Development and Validation of Glipizide, an Antidiabetic Drug, by RP-UPLC with Application to Formulated Forms and Urine

<table class="table-group" width="800px"><tr class="fig-image" id="a"><td><img alt="738397.fig.004a" src="https://static.hindawi.com/articles/isrn/volume-2013/738397/figures/738397.fig.004a.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(a) </b>Placebo blank</td></tr></table></td></tr><tr class="fig-image" id="b"><td><img alt="738397.fig.004b" src="https://static.hindawi.com/articles/isrn/volume-2013/738397/figures/738397.fig.004b.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(b) </b>Tablet extract</td></tr></table></td></tr></table>

<table>Chromatograms obtained for placebo blank and tablet extract.</table>

International Scholarly Research Notices

fig4

Figure 4

Figure 4: Quality by Design Approach for the Development and Validation of Glipizide, an Antidiabetic Drug, by RP-UPLC with Application to Formulated Forms and Urine 

Figure 4 | Quality by Design Approach for the Development and Validation of Glipizide, an Antidiabetic Drug, by RP-UPLC with Application to Formulated Forms and Urine 